SCHEMBL51871

SCHEMBL51871

CN(C(=O)OCc1ccccc1)C(C(N)=NO)C1CCC(CO)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 1/20 0.40
ITGA2B P08514 1/20 0.40
ABCB1 P08183 2/20 0.38
SIGMAR1 Q99720 1/20 0.38
PTGIR P43119 1/20 0.36
CTSL P07711 1/20 0.35
CTSB P07858 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
CYP2C19 P33261 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TSHR P16473 2/20 0.34
CYP3A4 P08684 3/20 0.34
CYP2C9 P11712 1/20 0.34
CPB1 P15086 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM5 P08912 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
ALDH1A1 P00352 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL51870 1.00 ITGB3 (0.40) ITGB3ITGA2BABCB1SIGMAR1PTGIR
SCHEMBL52319 0.81 ITGB3 (0.33) ITGB3ITGA2BABCB1SIGMAR1CTSL
SCHEMBL52318 0.81 ITGB3 (0.33) ITGB3ITGA2BABCB1SIGMAR1CTSL
SCHEMBL52317 0.81 ITGB3 (0.33) ITGB3ITGA2BABCB1SIGMAR1CTSL
SCHEMBL63846 0.80 ITGB3 (0.42) ITGB3ITGA2BABCB1SIGMAR1PTGIR
SCHEMBL52324 0.78 ITGB3 (0.41) ITGB3ITGA2BABCB1SIGMAR1PTGIR
SCHEMBL25182319 0.75 ABCB1 (0.48) ITGB3ITGA2BABCB1SIGMAR1CTSL
SCHEMBL23298120 0.71 SIGMAR1 (0.52) ITGB3ITGA2BABCB1SIGMAR1CTSL
SCHEMBL25179444 0.71 SIGMAR1 (0.49) ITGB3ITGA2BABCB1SIGMAR1CTSL
SCHEMBL23298118 0.71 SIGMAR1 (0.52) ITGB3ITGA2BABCB1SIGMAR1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280981-B1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-04-23 EP disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG ITGB3 2078/4885ITGA2B 1968/4885ABCB1 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.